Suchen
Biohaven Ltd
BHVNZur Watchlist hinzufügen
13.500USD
-0.330-2.39%
Handelsschluss 07-31 16:00（ET）Kurse um 15 Minuten verzögert
2.03BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biohaven Ltd Unternehmen
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Biohaven Ltd Informationen
BörsenkürzelBHVN
Name des UnternehmensBiohaven Ltd
IPO-datumSep 23, 2022
CEOCoric (Vlad)
Anzahl der mitarbeiter256
WertpapierartOrdinary Share
GeschäftsjahresendeSep 23
Addresse215 Church Street
StadtNEW HAVEN
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl06510
Telefon12034040410
Websitehttps://www.biohaven.com/
BörsenkürzelBHVN
IPO-datumSep 23, 2022
CEOCoric (Vlad)
Führungskräfte von Biohaven Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Ms. Kimberly Gentile
Ms. Kimberly Gentile
Senior Vice President of Clinical Operations
Senior Vice President of Clinical Operations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
2.02M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
195.65K
+0.28%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
67.72K
+45.11%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Biohaven Ltd?
Die fünf größten Anteilseigner von Biohaven Ltd sind: Dr. Gregory Hugh (Greg) Bailey, M.D.
Wie viele Institutionen halten Anteile an Biohaven Ltd (BHVN)?
Mit Stand vom 2026Q1 halten 610 Institutionen Anteile an Biohaven Ltd, mit einem Gesamtmarktwert von etwa 138.20M, was 91.79% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 37866485.00 gestiegen.